New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 17, 2012
06:28 EDTHEBHemispherx's fatigue drug to be reviewed again by FDA, WSJ reports
A potential treatment for chronic fatigue syndrome will be reviewed again this week when an FDA panel looks at Hemispherx Biopharma's (HEB) experimental drug Ampligen, reports the Wall Street Journal. The drug has been in development for chronic fatigue syndrome for about two decades, but in 2009 the FDA refused to approve it, saying clinical studies submitted for approval of the product didn't provide "credible evidence" of the drug's effectiveness. Reference Link
News For HEB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 26, 2015
10:01 EDTHEBHemispherx says court upholds defense in case brought by Cato Capital
Hemispherx Biopharma announced that on Friday the Third Circuit Court of Appeals upheld the company's defense of a case brought by Cato Capital, one of its former investment banks, thus affirming the trial court judgment Hemispherx obtained in September 2014, when the company fully prevailed in a federal lawsuit brought against the company following trial. The appellate panel affirmed the United States District Court for the District of Delaware, which had dismissed all claims against Hemispherx and subsequently ordered Cato to pay Hemispherx attorney's fees and costs in the amount of $770,852.76.The company's President, Thomas K. Equels, stated: "We are gratified that the distinguished panel vindicated our interpretation of the contract. Our lead counsel, James J. Black, III did an outstanding job interpreting this Delaware law based agreement, and properly navigating this dispute through the courts. Now, in furtherance of our corporate policy to seek redress against plaintiffs who bring meritless claims against the company, we will pursue Cato Capital to the fullest extent of the law to collect on the award of attorney's fees and costs."
August 24, 2015
08:37 EDTHEBHemispherx enters into supply agreement with Gulf Coast Regional Blood Center
Subscribe for More Information
August 19, 2015
14:02 EDTHEBHemispherx to hold an open house
Subscribe for More Information
August 17, 2015
08:47 EDTHEBHemispherx extends strategic alliance with Armada Health Care
Hemispherx Biopharma announced that as the company works toward the re-launch of Alferon N, it has extended its agreement with Armada Health Care for two years, through August 14, 2017, for the sales/marketing of Alferon N Injection, its FDA approved natural interferon, in the U.S. Under this Agreement, the Company will manufacture and supply Alferon N Injection to physicians and patients through Armada's national network of specialty pharmacies. Armada has agreed to provide ongoing sales and marketing to support the product's re-launch. Specialty Distributor, BioRidge Pharma, has received a two year contract extension and will warehouse, ship, and distribute Alferon N Injection on an exclusive basis for U.S. sales.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use